In addition to DTA, mutations of DNA damage-repairing genes PPM1D and TP53 are also crucial in CH pathogenesis, and mutations of these two genes can be frequent in t-MN. This evidence concerns the gene PPM1D and therapy-related myeloid neoplasm.